Completed PHASE2 INTERVENTIONAL 3-arm NCT00224770

Minimally Invasive Surgery and rtPA for Intracerebral Hemorrhage Evacuation (MISTIE)

Sponsor: Daniel Hanley

Interventions Intraoperative stereotactic CT-Guided Endoscopic Surgery MIS+Cathflo Activase (drug)

Updated 7 times since 2017 Last updated: Jun 17, 2015 Started: Aug 31, 2005 Primary completion: Aug 31, 2012 Completion: Apr 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Intracerebral Hemorrhage, this trial is completed. The trial is conducted by Daniel Hanley and has accumulated 7 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Aug 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Daniel Hanley
Emissary International LLC
Genentech, Inc.
National Institute of Neurological Disorders and Stroke (NINDS)

Data source: Johns Hopkins University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Birmingham, United States , Charleston, United States , Chicago, United States , Cincinnati, United States , Cleveland, United States , Detroit, United States , Edison, United States , Evanston, United States , Hartford, United States and 15 more locations